New hope for HIV patients with stubborn hepatitis c?
NCT ID NCT00221650
First seen May 15, 2026 · Last updated Jun 10, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs, peginterferon alfa2a and ribavirin, in 17 adults with both HIV and chronic hepatitis C who had not responded to a previous hepatitis C treatment. The goal was to see if this second-line treatment could clear the hepatitis C virus from the blood for at least 24 weeks after stopping therapy. The approach involved weekly injections and daily pills for 48 weeks, while monitoring safety and effects on HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C, CHRONIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD
Bordeaux, 33076, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.